Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients With COVID-19

Next Previous
Trial Profile

A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients With COVID-19

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 15 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amubarvimab/romlusevimab-Brii-Biosciences (Primary) ; Bamlanivimab (Primary) ; Cilgavimab/tixagevimab (Primary) ; Cilgavimab/tixagevimab (Primary) ; Ensovibep (Primary) ; Sotrovimab (Primary) ; Remdesivir
  • Indications COVID 2019 infections; SARS-CoV-2 acute respiratory disease
  • Focus Therapeutic Use
  • Acronyms ACTIV-3; TICO

    • Most Recent Events

    • 09 Nov 2023 Results (n=2149) published in the Journal of Infectious Diseases
    • 23 Aug 2023 Status changed from active, no longer recruiting to completed.
    • 18 Aug 2023 This trial has been completed in Denmark (Date of the global end of the trial: 14-Jul-2023), according to the European Clinical Trials Database record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top